Bundibugyo ebolavirus outbreak highlights gaps in vaccine preparedness for neglected tropical diseases
The Bundibugyo ebolavirus outbreak in Congo and Uganda has exposed a critical gap in international vaccine preparedness, as there is no licensed vaccine for this rare species. The article explains the complex and costly process of vaccine development, requiring BSL-4 facilities, primate trials, and substantial funding. It highlights that neglected tropical diseases (NTDs) like Bundibugyo ebolavirus suffer from "neglect" due to small commercial markets, lack of financial incentives for pharmaceutical companies, and the diseases primarily affecting poor, rural, and politically marginalized populations. Despite international declarations and initiatives, R&D remains patchy, compounded by weak healthcare systems.
Key Points
- The Bundibugyo ebolavirus outbreak reveals a lack of licensed vaccines for this specific species.
- Vaccine development for such rare and neglected diseases is hindered by high costs, limited commercial incentives, and weak R&D infrastructure.
- Neglected Tropical Diseases (NTDs) disproportionately affect poor and marginalized populations, leading to insufficient investment.
- International efforts and declarations aim to address NTDs, but challenges in R&D and healthcare delivery persist.
Exam Facts
- Virus: Bundibugyo ebolavirus (BDBV).
- Outbreak location: Democratic Republic of the Congo and Uganda.
- Biosafety Level (BSL) 4 facilities: Required for handling deadly viruses like ebolavirus.
- Declarations: London Declaration (2012), Kigali Declaration (2022) for NTDs.
Read it. Retain it. Recall it.
Get spaced-repetition flashcards, daily quizzes and offline access — free on Android.